Liso-Cel in Relapsed/Refractory Marginal Zone Lymphoma

Non-interventional Cohort Study of Patients Treated With Liso-Cel (Lisocabtagene Maraleucel) for Relapsed/Refractory Marginal Zone Lymphoma in the Postmarketing Setting

This non-interventional study will use information already reported to the Center for International Blood and Marrow Transplant Research (CIBMTR) registry during routine clinical care. The study will assess the long-term safety and effectiveness of lisocabtagene maraleucel in participants with relapsed/refractory marginal zone lymphoma.

Inclusion Criteria:

Participants who meet the following eligibility criteria will be selected from the registry:

• Participants of 18 years of age or older at the time of infusion

• Participants with a diagnosis of relapsed or refractory marginal zone lymphoma (R/R MZL)

• Participants have received at least two prior lines of systemic therapy

• Participants have been treated in the postmarketing setting with at least 1 infusion of lisocabtagene maraleucel:

  • used for the treatment of R/R MZL,
  • within the FDA-approved indication and dosage per the United States prescribing information and
  • product specifications approved for commercial release in the USA.

• Participants have consented to share their data with the registry and the Sponsor.

Exclusion Criteria:

Participants who meet the following exclusion criterion will not be eligible for selection from the registry:

• Participants known to be participating in investigational studies at the time of lisocabtagene maraleucel infusion.